News
DRRX
0.9159
+3.67%
0.0324
Weekly Report: what happened at DRRX last week (0415-0419)?
Weekly Report · 3d ago
Weekly Report: what happened at DRRX last week (0408-0412)?
Weekly Report · 04/15 12:16
Weekly Report: what happened at DRRX last week (0401-0405)?
Weekly Report · 04/08 12:22
Oppenheimer Reiterates Outperform on Durect, Maintains $5 Price Target
Benzinga · 04/01 13:19
Weekly Report: what happened at DRRX last week (0325-0329)?
Weekly Report · 04/01 12:18
HC Wainwright & Co. Reiterates Neutral on Durect
Benzinga · 03/28 12:11
H.C. Wainwright Keeps Their Hold Rating on Durect (DRRX)
TipRanks · 03/28 10:27
DRRX Stock Earnings: Durect Beats EPS, Beats Revenue for Q4 2023
Durect reported earnings per share of -10 cents. The company reported revenue of $2.67 million. This was 7.62% better than the analyst estimate for the company to report revenue of -7.5 million. Durect also reported better than expected quarterly earnings.
Investorplace · 03/28 00:53
Durect (DRRX) Reports Q4 Loss, Misses Revenue Estimates
NASDAQ · 03/27 21:10
DURECT Corp reports results for the quarter ended in December - Earnings Summary
DURECT Corp reports results for the quarter ended in December. The company reported a quarterly adjusted loss of 10 cents per share. Revenue fell 19.5% to $2.67 million from a year ago. DURECT shares had risen by 115.3% this quarter.
Reuters · 03/27 21:01
DURECT Corp. Q4 Loss decreases, beats estimates
NASDAQ · 03/27 20:29
Durect: Q4 Earnings Insights
Durect reports its Q4 earnings on March 27. The company beat estimates by 70.0%. Revenue was down $646 thousand from the same period last year. Durect is expected to report its earnings on Wednesday, March 27 at 4:00 p.m.
Benzinga · 03/27 20:15
Durect Q4 2023 GAAP EPS $(0.10) Beats $(0.33) Estimate, Sales $2.669M Beat $2.477M Estimate
Durect reported quarterly losses of $0.10 per share and sales of $2.669 million. The company beat the analyst consensus estimate by 69.7 percent. Durect's sales for the quarter were down 19.49 percent from the same period last year.
Benzinga · 03/27 20:05
*Durect 4Q Rev $2.67M >DRRX
Dow Jones · 03/27 20:01
Press Release: DURECT Corporation Reports Fourth -2-
This press release contains forward-looking statements. Larsucosterol is an investigational drug candidate under development and has not been approved for commercialization. Actual results may differ from those contained in the forward- looking statements. DURECT Corporation is a subsidiary of Innocoll Pharmaceuticals.
Dow Jones · 03/27 20:01
*Durect 4Q Loss $1.44M >DRRX
Dow Jones · 03/27 20:01
*Durect 4Q Loss/Shr 10c >DRRX
Dow Jones · 03/27 20:01
After-Hours Earnings Report for March 27, 2024 : AMS, AQMS, BCDA, BRZE, CELC, CXM, DRRX, EAST, FC, FUL, GREE, JEF
NASDAQ · 03/27 18:00
Durect: Q4 Earnings Snapshot
Durect Corp. Reported a loss of $1.4 million in its fourth quarter. The specialty pharmaceutical company posted revenue of $2.7 million in the period. For the year, the company reported a Loss of $27.6 million. The results exceeded Wall Street expectations.
Barchart · 03/27 15:19
Options Volatility and Implied Earnings Moves Today, March 27, 2024
TipRanks · 03/27 12:05
More
Webull provides a variety of real-time DRRX stock news. You can receive the latest news about DURECT through multiple platforms. This information may help you make smarter investment decisions.
About DRRX
DURECT Corporation is a late-stage biopharmaceutical company pioneering the development of epigenetic therapies that target dysregulated deoxyribonucleic acid (DNA) methylation to transform the treatment of serious and life-threatening conditions, including acute organ injury and cancer. Larsucosterol is in clinical development for the potential treatment of alcohol-associated hepatitis, for which United States Food and Drug Administration (FDA) has granted a Fast Track Designation; metabolic dysfunction-associated steatohepatitis is also being explored. Its commercial pharmaceutical products include POSIMIR (bupivacaine solution), PERSERIS (schizophrenia) and Methydur Sustained Release Capsules (ADHD). POSIMIR (bupivacaine solution) for infiltration use, a non-opioid analgesic utilizing the SABER platform technology, is FDA-approved. Its ALZET product line consists of miniature, implantable osmotic pumps and accessories used for research in mice, rats and other laboratory animals.